Allogeneic fibroblast cell therapy in the treatment of recessive dystrophic epidermolysis bullosa
- 5 April 2018
- journal article
- Published by Elsevier in Wound Medicine
- Vol. 21, 8-11
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelinesBritish Journal of Dermatology, 2015
- Inherited epidermolysis bullosa: Updated recommendations on diagnosis and classificationJournal of the American Academy of Dermatology, 2014
- Collagen VII plays a dual role in wound healingJournal of Clinical Investigation, 2013
- Fibroblast-Based Cell Therapy Strategy for Recessive Dystrophic Epidermolysis BullosaDermatologic Clinics, 2010
- Mechanisms of Fibroblast Cell Therapy for Dystrophic Epidermolysis Bullosa: High Stability of Collagen VII Favors Long-term Skin IntegrityMolecular Therapy, 2009
- Potential of Fibroblast Cell Therapy for Recessive Dystrophic Epidermolysis BullosaJournal of Investigative Dermatology, 2008
- A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapyJournal of Clinical Investigation, 2008
- Fibroblasts as Target Cells for DEB Gene TherapyJournal of Investigative Dermatology, 2006
- Fibroblasts Show More Potential as Target Cells than Keratinocytes in COL7A1 Gene Therapy of Dystrophic Epidermolysis BullosaJournal of Investigative Dermatology, 2006
- Normal and Gene-Corrected Dystrophic Epidermolysis Bullosa Fibroblasts Alone Can Produce Type VII Collagen at the Basement Membrane ZoneJournal of Investigative Dermatology, 2003